J
Joëlle Blumberg
Researcher at Ipsen
Publications - 27
Citations - 2790
Joëlle Blumberg is an academic researcher from Ipsen. The author has contributed to research in topics: Lanreotide & Triptorelin. The author has an hindex of 16, co-authored 27 publications receiving 2441 citations.
Papers
More filters
Journal ArticleDOI
Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
Martyn Caplin,Marianne Pavel,Jarosław B. Ćwikła,Alexandria T. Phan,Markus Raderer,Eva Sedlackova,Guillaume Cadiot,Edward M. Wolin,Jaume Capdevila,Lucy Wall,Guido Rindi,Alison Langley,Séverine Martinez,Joëlle Blumberg,Philippe Ruszniewski +14 more
TL;DR: Lanreotide was associated with significantly prolonged progression-free survival among patients with metastatic enteropancreatic neuroendocrine tumors of grade 1 or 2 (Ki-67 <10%) and the therapeutic effect in predefined subgroups was generally consistent with that in the overall population.
Journal ArticleDOI
International Society for Pediatric and Adolescent Diabetes
Caroline Brain,M. Hubbard,Michael A. Preece,M.O. Savage,Albert Aynsley-Green,Olivier Bouchot,Jean Yves Soret,Didier Jacqmin,Najiba Lahlou,Marc Roger,Joëlle Blumberg,Vallo Tillmann,Stephen M Shalet,David Price,Jeremy K.H. Wales,Louise Pennells,Joanne Soden,Matthew S. Gill,A. J. Whatmore,Peter E. Clayton,Giorgio Radetti,Lucia Ghizzoni,C. Paganini,Lorenzo Iughetti,G. Caselli,S. Bernasconi,Meir Lampit,Tova Nave,Zeev Hochberg,Rafael Artuch,Carlos Pavía,Ana Playán,Maria Antonia Vilaseca,Jaume Colomer,Carme Valls,Miquel Rissech,María Antonia González,Adolf Pou,Paz Briones,Julio Montoya,Mercè Pineda,P. Brogan,V.V. Khadilkar,Richard Stanhope,Fredrik Cederblad,Uwe Ewald,Jan Gustafsson +46 more
TL;DR: International Society for Pediatric and Adolescent Diabetes 24th Annual Meeting, Zurich, Switzerland, September 14–17, 1998 Horm Res 1998;50:107–140 Abstracts Dr. Michael S. Harbuz Division of Medicine, Bristol Bristol Royal Infirmary, Marlborough Street Bristol BS2 8HW.
Journal ArticleDOI
Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance.
Dermot O'Toole,Michel Ducreux,G Bommelaer,J L Wemeau,Olivier Bouché,F Catus,Joëlle Blumberg,Philippe Ruszniewski +7 more
TL;DR: In this paper, a comparison between octreotide and lanreotide in terms of patient acceptability, patient preference, and efficacy in controlling symptoms was performed in patients with carcinoid syndrome.
Journal ArticleDOI
The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors
Michel Ducreux,Philippe Ruszniewski,Jean-Alain Chayvialle,Joëlle Blumberg,Denis Cloarec,Henri Michel,Jean Michel Raymond,Jean-Louis Dupas,Hervé Gouerou,Raymond Jian,Elisabeth Genestin,Pascal Hammel,Philippe Rougier +12 more
TL;DR: Lanreotide is safe and well tolerated in patients with carcinoid tumors, and seems to have both symptomatic and antitumoral effects in this setting.
Journal ArticleDOI
Final Height after Long-Term Treatment with Triptorelin Slow Release for Central Precocious Puberty: Importance of Statural Growth after Interruption of Treatment
Jean-Claude Carel,Marc Roger,Simona Ispas,Françoise Tondu,Najiba Lahlou,Joëlle Blumberg,Jean-Louis Chaussain +6 more
TL;DR: The influence of the posttreatment growth spurt suggests that continuing treatment beyond the age of 11 yr in girls does not improve and could actually decrease FH, and this point should be evaluated in a formal controlled trial.